Mississauga, Canada (September 2020) Red Leaf Medical Inc. is delighted to announce the Canadian launch of INSTYLAN™, a new brand of Hyaluronic Acid (HA) for bladder instillation.
INSTYLAN™ is indicated to treat Interstitial Cystitis (IC)/Bladder Pain Syndrome (BPS). Typical symptoms of IC/BPS include pelvic pain, frequency, nocturia, and urgency to urinate. Approximately 330,000 to 800,000 women in Canada are affected by symptoms of IC/BPS. Of these women, however, only 9.7% report being diagnosed with the condition.
The use of HA in the treatment of IC/BPS has been recommended as an option (Grade C) in the CUA guideline: Diagnosis and treatment of interstitial cystitis/bladder pain syndrome – “HA is thought to help improve or recreate the defective bladder GAG layer in IC/BPS. Several observational studies have reported a wide range of response rates, from 30‒87%”
In the CUA Best Practice Report: Diagnosis and management of radiation-induced hemorrhagic cystitis (RHC) the following statement is made – “Intravesical therapy with HA may improve symptoms of RHC and may provide further benefit in those with significant LUTS. (Grade 3C)”
The user-friendly packaging enables patients to do the instillation with a catheter in the convenience of their home. The additional port can be used to add other drugs such as lidocaine, chondroitin sulphate, etc. based on physicians’ recommendation.
INSTYLAN™ is an exciting new product and is complementary to Red Leaf Medical’s portfolio of urological products and services, including CathetersPLUS™.
About Red Leaf Medical Inc.
Red Leaf Medical is the only Canadian healthcare company focused exclusively on providing innovative products and services to the urology market. The company’s portfolio includes products in uro-oncology, male and female incontinence, pediatric urology, and infertility. Red Leaf Medical was ranked as one of Canada’s fastest growing companies in Canadian Business magazine’s PROFIT 500 listing in 2015, 2016 and 2017.
